Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024 The vendor landscape of the global market for human vaccines features a markedly high level of consolidation, with the companies Merck & Co, Inc., GlaxoSmithKline plc., and Sanofi, Pfizer, Inc., collectively accounting for over 70% of the overall market in 2015, notes Transparency Market Research in a recent report. To outplay competitors, companies are focusing on establishing ties with national and international healthcare bodies, strengthening distribution chains, and investing funds in the development and deployment of innovative and more efficient storage and transportation techniques. Transparency Market Research states that the global human vaccines market will exhibit a promising 11.2% CAGR from 2016 through 2024, rising from a valuation of US$28.3 bn in 2015 to US$72.5 bn by 2024. Combination Vaccines to See Increased Rate of Adoption Based on the type of vaccine, the market for human vaccines has been examined in the report for conjugate vaccines, recombinant